Table 3.

Patient withdrawal due to adverse events: first course of anti-TNF therapy

Adverse event leading to withdrawal (MedDRA system organ classification)	Etanercept (n = 316)	Infliximab (n = 162)	Adalimumab (n = 88)
Immune system disordersa	2 (0.6)	12 (7.4)	1 (1.1)
General disorders and administration site conditionsb	2 (0.6)	2 (1.2)	0 (0.0)
Infections and infestations	15 (4.7)	3 (1.9)	3 (3.4)
Gastrointestinal disorders	4 (1.3)	4 (2.5)	1 (1.1)
Hepatobiliary disorders	1 (0.3)	2 (1.2)	0 (0.0)
Respiratory, thoracic and mediastinal disorders	1 (0.3)	0 (0.0)	0 (0.0)
Renal and urinary disorders	1 (0.3)	1 (0.6)	0 (0.0)
Cardiac disorders	1 (0.3)	3 (1.9)	0 (0.0)
Blood and lymphatic system disorders	2 (0.6)	1 (0.6)	2 (2.3)
Nervous system disorders	3 (0.9)	5 (3.1)	1 (1.1)
Skin and subcutaneous tissue disorders	3 (0.9)	3 (1.9)	3 (3.4)
Metabolism and nutrition disorders	0 (0.0)	0 (0.0)	1 (1.1)
Psychiatric disorders	1 (0.3)	0 (0.0)	0 (0.0)
Neoplasms benign, malignant and unspecified (including cysts and polyps)	3 (0.9)	2 (1.2)	1 (1.1)
Total	39 (12.3)	38 (23.5)	13 (14.8)

Data presented as n (%). ^aIncludes drug hypersensitivity. ^bIncludes one death of unknown cause.